Sun Pharma signed a global exclusive licensing deal with LIB Therapeutics to commercialize a cholesterol-lowering drug outside the US and China, sparking bullish brokerage views

Tue 29 Sep 2026

Addressable market outside US/China

$3.7 billion

Europe market share

$2.9 billion

Specialty pharma sales

1.3 billion dollars

Ilumya sales

800 million USD

FY26 EPS estimate

₹50

Heard on Live TV News Channel between 08:50:57 - 08:52:12 IST.

• Sun Pharma signed an exclusive global licensing agreement with privately-held Cincinnati-based LIB Therapeutics for a PCSK9 inhibitor cholesterol drug
• Deal covers commercialization and manufacturing rights in all markets except US and China, with addressable sales estimated at $3.7 billion, including $2.9 billion from Europe
• Drug is administered once a month and offers easier storage versus rival therapies
• Brokerages including Macquarie and another maintained buy ratings citing 21.5% upside potential, saying the deal strengthens Sun Pharma's innovative and specialty portfolio
• Panelist noted Sun Pharma's specialty pharma sales have reached $1.3 billion with high margins, and expects EPS to rise from ₹50 in FY26 to ₹110 in FY29 partly due to the Ohm/organon acquisition doubling EBITDA without equity dilution

The call above is Macquarie's, reported here as they made it. Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.